Phase I Infusional Cyclophosphamide and Pulse Dexamethasone With Rapamycin and Hydroxychloroquine in Patients With Relapsed or Refractory Myeloma
This protocol will enroll subjects who have multiple myeloma that has returned after treatment or has stopped responding to treatment. The purpose of this study is to test the safety of rapamycin and hydroxychloroquine (study drugs) at different dose levels. We believe that the combination of standard chemotherapy with the study drugs may improve the response outcome compared to standard chemotherapy alone.
Relapsed or Refractory Multiple Myeloma
Subjects should have relapsed/ refractory multiple myeloma.
Subjects should be 18 years or older.
Subjects should not have an uncontrolled intercurrent illness.
18 - 99
Healthy Volunteers Needed
Duration of Participation
Up to 24 months